| Literature DB >> 24881821 |
Cheryl S Broussard1, Meghan T Frey2, Sonia Hernandez-Diaz3, Michael F Greene4, Christina D Chambers5, Leyla Sahin6, Beth A Collins Sharp7, Margaret A Honein8.
Abstract
To address information gaps that limit informed clinical decisions on medication use in pregnancy, the Centers for Disease Control and Prevention (CDC) solicited expert input on a draft prototype outlining a systematic approach to evaluating the quality and strength of existing evidence for associated risks. The draft prototype outlined a process for the systematic review of available evidence and deliberations by a panel of experts to inform clinical decision making for managing health conditions in pregnancy. At an expert meeting convened by the CDC in January 2013, participants divided into working groups discussed decision points within the prototype. This report summarizes their discussions of best practices for formulating an expert review process, developing evidence summaries and treatment guidance, and disseminating information. There is clear recognition of current knowledge gaps and a strong collaboration of federal partners, academic experts, and professional organizations willing to work together toward safer medication use during pregnancy. Published by Elsevier Inc.Entities:
Keywords: Centers for Disease Control and Prevention; expert review; medications; pregnancy; teratogens
Mesh:
Year: 2014 PMID: 24881821 PMCID: PMC4484789 DOI: 10.1016/j.ajog.2014.05.040
Source DB: PubMed Journal: Am J Obstet Gynecol ISSN: 0002-9378 Impact factor: 8.661